TR201809537T4 - Ataksik bir hastalığın önlenmesi veya tedavi edilmesinde kullanım için piridazin türevleri. - Google Patents

Ataksik bir hastalığın önlenmesi veya tedavi edilmesinde kullanım için piridazin türevleri. Download PDF

Info

Publication number
TR201809537T4
TR201809537T4 TR2018/09537T TR201809537T TR201809537T4 TR 201809537 T4 TR201809537 T4 TR 201809537T4 TR 2018/09537 T TR2018/09537 T TR 2018/09537T TR 201809537 T TR201809537 T TR 201809537T TR 201809537 T4 TR201809537 T4 TR 201809537T4
Authority
TR
Turkey
Prior art keywords
hydroxypyridazine
disease
group
ataxia
ataxic
Prior art date
Application number
TR2018/09537T
Other languages
English (en)
Turkish (tr)
Inventor
Almond Sarah
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50554599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201809537(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of TR201809537T4 publication Critical patent/TR201809537T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TR2018/09537T 2014-03-06 2015-03-06 Ataksik bir hastalığın önlenmesi veya tedavi edilmesinde kullanım için piridazin türevleri. TR201809537T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1403944.0A GB201403944D0 (en) 2014-03-06 2014-03-06 New use

Publications (1)

Publication Number Publication Date
TR201809537T4 true TR201809537T4 (tr) 2018-07-23

Family

ID=50554599

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/09537T TR201809537T4 (tr) 2014-03-06 2015-03-06 Ataksik bir hastalığın önlenmesi veya tedavi edilmesinde kullanım için piridazin türevleri.

Country Status (32)

Country Link
US (1) US20170014407A1 (enExample)
EP (1) EP3113778B1 (enExample)
JP (1) JP6510549B2 (enExample)
KR (1) KR20160126081A (enExample)
CN (1) CN106102743A (enExample)
AU (1) AU2015225954B2 (enExample)
CA (1) CA2940342A1 (enExample)
CL (1) CL2016002151A1 (enExample)
CY (1) CY1120573T1 (enExample)
DK (1) DK3113778T3 (enExample)
EA (1) EA036438B1 (enExample)
ES (1) ES2676905T3 (enExample)
GB (1) GB201403944D0 (enExample)
GE (2) GEP20196984B (enExample)
HR (1) HRP20181082T1 (enExample)
IL (1) IL247435A0 (enExample)
LT (1) LT3113778T (enExample)
MA (1) MA39315A1 (enExample)
MX (1) MX2016010524A (enExample)
MY (1) MY202127A (enExample)
PH (1) PH12016501751A1 (enExample)
PL (1) PL3113778T3 (enExample)
PT (1) PT3113778T (enExample)
RS (1) RS57594B1 (enExample)
SG (1) SG11201607106YA (enExample)
SI (1) SI3113778T1 (enExample)
SM (1) SMT201800367T1 (enExample)
TR (1) TR201809537T4 (enExample)
TW (1) TW201534591A (enExample)
UA (1) UA123352C2 (enExample)
WO (1) WO2015132608A1 (enExample)
ZA (1) ZA201604611B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
PE20211761A1 (es) 2014-04-29 2021-09-07 Fmc Corp Herbicidas de piridazinona
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
BR112019028016B1 (pt) 2017-06-30 2023-12-05 Fmc Corporation Composto, composições herbicidas, mistura herbicida e método para controlar o crescimento de vegetação indesejada
CN112569217B (zh) * 2019-09-30 2022-04-22 厦门大学 戊酸衍生物在治疗遗传性小脑共济失调中的应用
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
EP4301367A1 (en) 2021-03-01 2024-01-10 Takeda Pharmaceutical Company Limited Use of luvadaxistat for the treatment of cognitive impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1084704B1 (en) * 1998-06-10 2006-03-29 Meiji Seika Kaisha Ltd. Remedies for spinocerebellar ataxia and compositions for treating spinocerebellar ataxia
AU2002339696A1 (en) * 2001-12-03 2003-06-17 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
JO3115B1 (ar) * 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao

Also Published As

Publication number Publication date
DK3113778T3 (en) 2018-07-30
WO2015132608A1 (en) 2015-09-11
CA2940342A1 (en) 2015-09-11
JP6510549B2 (ja) 2019-05-08
EA201691566A1 (ru) 2016-12-30
GB201403944D0 (en) 2014-04-23
PL3113778T3 (pl) 2018-11-30
SG11201607106YA (en) 2016-09-29
ZA201604611B (en) 2017-09-27
SI3113778T1 (en) 2018-08-31
AU2015225954A1 (en) 2016-07-07
LT3113778T (lt) 2018-08-27
EP3113778B1 (en) 2018-06-06
KR20160126081A (ko) 2016-11-01
AU2015225954B2 (en) 2020-06-18
CY1120573T1 (el) 2019-07-10
EA036438B1 (ru) 2020-11-11
US20170014407A1 (en) 2017-01-19
GEAP201914284A (en) 2019-02-25
TW201534591A (zh) 2015-09-16
MY202127A (en) 2024-04-05
PH12016501751A1 (en) 2017-02-06
CL2016002151A1 (es) 2016-12-30
ES2676905T3 (es) 2018-07-26
MA39315A1 (fr) 2017-09-29
PT3113778T (pt) 2018-07-11
RS57594B1 (sr) 2018-11-30
GEP20196984B (en) 2019-06-25
JP2017507156A (ja) 2017-03-16
HRP20181082T1 (hr) 2018-09-07
CN106102743A (zh) 2016-11-09
UA123352C2 (uk) 2021-03-24
IL247435A0 (en) 2016-11-30
MX2016010524A (es) 2016-10-31
SMT201800367T1 (it) 2018-09-13
EP3113778A1 (en) 2017-01-11

Similar Documents

Publication Publication Date Title
EP3113778B1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
US12201631B2 (en) Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and fragile X syndrome
JP5605659B2 (ja) 細胞保護剤
US20140241990A1 (en) Methods of using adenosine a1 receptor activation for treating depression
JP6668045B2 (ja) ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
Liu et al. A dystonia-like movement disorder with brain and spinal neuronal defects is caused by mutation of the mouse laminin β1 subunit, Lamb1
EA027840B1 (ru) Производные пиридазина, композиции и способы лечения когнитивного нарушения
JP2026001049A (ja) うつ病性障害の治療方法
EA017915B1 (ru) Kcnq-открыватели калиевых каналов, применяемые для лечения или ослабления симптомов шизофрении
JP2008542417A (ja) 進行性ミオクローヌスてんかんに特徴付けられる疾患の治療用ブリバラセタムの使用
US20220273662A1 (en) Use of sildenafil and rock inhibitors for treating stroke or sequelae following stroke
HK1230925A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
US10034848B2 (en) Increase of protein synthesis ameliorates synaptopathy-related neurological disorders
WO2022079304A1 (en) Compositions and uses thereof
WO2026010871A1 (en) ((pyrrolopyridine-3-carbonyl) imino)-2,3-dihydrothiazol-4-yl) methyl phosphates for activating yap
WO2025042610A1 (en) Pifithrin analogues and methods of treating rett syndrome
EP4208161A1 (en) Compositions and uses thereof
Brumley The ontogeny of interlimb coordination during serotonin-induced hindlimb stepping in the perinatal rat
Manschot et al. Long‐term angiotensin converting enzyme inhibition dose‐dependently improves nerve conduction velocity and evoked potential latencies in streptozotocin‐diabetic rats
Heinz et al. How much fear is in anxiety?
UA9407U (en) Method for treating diabetic retinopathy